Chronic Kidney Disease after Nonmyeloablative Stem Cell Transplantation in Adults  by Kersting, Sabina & Verdonck, Leo F.
Biology of Blood and Marrow Transplantation 14:403-408 (2008)
Q 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/1404-0001$32.00/0
doi:10.1016/j.bbmt.2007.12.495Chronic Kidney Disease after Nonmyeloablative Stem
Cell Transplantation in AdultsSabina Kersting, Leo F. Verdonck
Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
Correspondence and reprint requests: Sabina Kersting, MD, Department of Hematology, B02.226, University Medical
Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands (e-mail: s.kersting@umcutrecht.nl).
Received December 18, 2007; accepted December 26, 2007
ABSTRACT
Chronic kidney disease (CKD) aftermyeloablative stem cell transplantation (SCT) is a well-established problem.
Little is known about CKD after nonmyeloablative SCT. We performed a retrospective cohort study of 108
adults who received nonmyeloablative SCT with fludarabine and/or total-body irradiation (TBT) conditioning.
Renal function was assessed by estimating glomerular filtration rate (GFR) with theMDRD equation. CKDwas
defined as GFR\60 mL/min/1.73 m2. CKD developed in 15% of patients after a median of 15 months. None
of the patients required dialysis. Cumulative incidence of CKD was 7% at 12 months, 14% at 24 months, and
22% at 48 months. Risk factors for CKD were female sex (P 5 .021), older age (P 5 .040), and lower GFR pre-
transplant (P\ .001). Complications after SCT were not associated with CKD. SCT nephropathy, a cause of
CKD after myeloablative SCT, did not occur. Overall survival (OS) was 66%. There was no difference in survival
between patients with or without CKD. In conclusion, CKD is a frequent complication after nonmyeloablative
SCT and is not related to SCT nephropathy. Women, patients above 50 years of age, and patients with slightly
decreased kidney function pretransplant have the greatest risk of development of CKD.
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Because treatment-related morbidity and mortality
(TRM) limit the success of myeloablative stem cell
transplantation (SCT), a nonmyeloablative SCT regi-
men was developed. This regimen would be suitable
for patients of older age and also for patients with co-
morbid conditions who were not eligible for myeloa-
blative SCT [1]. Differences between myeloablative
and nonmyeloablative conditioning are a reduction in
intensities of both chemotherapy and total-body irradi-
ation (TBI) in the nonmyeloablative approach. Because
patients’ characteristics and transplant procedures are
different in the 2 regimens, it is likely that transplant-re-
lated organ dysfunction after transplantation will be
different also.
Chronic kidney disease (CKD) after myeloablative
SCT is a well-established problem. Incidence of CKD
after myeloablative SCT ranges between 7% and 66%,
dependent on different definitions that were used [2-
9]. Two recent large studies showed an incidence ofCKD (defined according to Kidney Disease Outcomes
Quality Initiative [K/DOQI] as an estimated glomeru-
lar filtration rate [GFR] of\60 mL/min/1.73 m2 for
more than 3 months) [10] after myeloablative SCT
of 22.3% and 23%, respectively [11,12]. Detection of
patients with CKD is important, because these patients
have adverse outcomes, such as kidney failure, cardio-
vascular disease, and premature death, which can be
prevented or delayed by interventions [10]. A subset
of patients with CKD after myeloablative SCT has
a thrombotic microangiopathic syndrome known as
SCT nephropathy, radiation nephritis, or condition-
ing-associated homolytic uremic syndrome, wherein
TBI is the most probable cause [13-24]. These patients
have a higher risk for development of end-stage renal
disease with increased mortality [3,12]. Because TBI
dose is lower in nonmyeloablative SCT, the develop-
ment of CKD might be less. However, patients receiv-
ing nonmyeloablative transplants are usually older,
and renal function declines with age [25], which may403
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SCT.
Until now, only 1 study describes chronic renal
dysfunction after nonmyeloablative SCT, with an in-
cidence of 66% defined by reduction of GFR of at
least 25% from baseline [26]. How many of these pa-
tients have a GFR\60 mL/min/1.73 m2 (K/DOQI
definition of CKD) is not clear from this study. This
particular cutoff is important because of the increased
prevalence of hypertension, anemia, derangements in
calcium-phosphorous metabolism, reduction in serum
albumin, and reductions in functional status that occur
below this cutoff [10].
The aim of the present study was to evaluate the
prevalence of CKD (defined as a GFR\60 mL/min/
173 m2) and to analyze risk factors of CKD in a large
cohort. Moreover, we wanted to study whether CKD
influenced survival.
PATIENTS AND METHODS
Patients
Between September 1, 2001, and October 1, 2005,
nonmyeloablative SCT was performed in 150 adults
aged 20-69 years, at the Department of Hematology
of the University Medical Center Utrecht. Because
the primary outcome of this study was CKD, we
excluded patients with a survival of\6 months (n 5
24) or with a GFR #60 mL/min/1.73 m2 (n 5 18)
within 1 month prior to transplantation. Patients
gave informed consent and were treated according to
clinical protocols approved by the local ethics review
board.
Methods
Of the 108 remaining patients, data were collected
and analyzed retrospectively using a database and pa-
tient records through December 1, 2006. The follow-
ing baseline variables were noted: sex, age, history of
autologous transplantation, history of hypertension
(defined as a blood pressure $140/80 mmHg or re-
ceiving antihypertensive medication), history of vascu-
lar disease (angina pectoris, myocardial infarction,
cerebrovascular event, and diabetes mellitus), diagno-
sis of hematologic disease, malignancy risk (low risk
malignancy: patients with acute leukemia in the first
complete remission, chronic myelogenous leukemia
(CML) in the first chronic phase, and untreated severe
aplastic anemia (AA); high-risk malignancy: all other
hematologic diseases), type of transplant (matched re-
lated donor, partially matched-related donor,
matched-unrelated donor), and conditioning regimen.
Serum creatinine was noted at 6 months, 8 months,
12 months, 18 months, and 24 months, and thereafter
annually. Renal function was assessed by estimating
GFR with the simplified Modification of Diet in Renal
Disease Study prediction equation: GFR 5 186.3 (serum creatinine)21.154  age20.203  (0.742 for
women) [10]. CKD was defined according to the
K/DOQI definition of kidney disease. Stage 3 CKD
was an estimated GFR\60 mL/min/1.73 m2, stage 4
CKD was a GFR\30 mL/min/1.73 m2, and stage 5
CKD was a GFR\15 mL/min/1.73 m2 or need for di-
alysis [10]. Only if low GFR persisted until death or last
follow-up was the patients defined as having CKD.
Acute renal failure was defined as occurrence of
renal dysfunction within 100 days after transplantation.
Acute renal failure was categorized as follows: grade 0
(or normal renal function) was equivalent to a de-
crease in estimated GFR of \25% of the value at
time of transplantation. Grade 1 corresponded to
a\2-fold rise in serum creatinine concentration, with
a decrease in estimated GFR of .25% of the value at
time of transplantation. Grade 2 corresponded to
a .2-fold rise in serum creatinine, without indication
for dialysis. Grade 3 corresponded to patients with
grade 2 parameters but requiring dialysis. This classifi-
cation of grades of acute renal failure is similar to other
studies on acute renal failure after SCT [26-28].
Nephrotic syndrome was defined as a urinary pro-
tein excretion .3.5 g/24 hours and hypoalbuminemia
with plasma levels\3 g/dL.
The following variables posttransplantation were
registered until last follow-up or death: acute and
chronic graft-versus-host disease (aGVHD, cGVHD),
cytomegalovirus (CMV) reactivation, admission to in-
tensive care unit (ICU), hypertension (defined as
a blood pressure$140/80 mmHg or receiving antihy-
pertensive medication), and cyclosporine trough levels.
SCT Procedure
The nonmyeloablative conditioning regimen con-
sisted of fludarabine (30 mg/m2/day for 3 days) fol-
lowed by TBI of 200 cGy (n 5 76) or TBI alone
(n 5 32). The graft was infused after TBI on day 0.
In recipients of a histocompatibility leukocyte antigen
(HLA)-matched unrelated donor or a single HLA-
antigen mismatched family donor, antithymocyte
globulin (Rabbit ATG, Thymoglobulin, Genzyme,
Cambridge, MA) was given before fludarabine was in-
fused, at a dose of 2 mg/kg/day for 4 days (n5 41). All
patients received GVHD prophylaxis orally with
cyclosporine and mycophenolate mofetil (MMF). Cy-
closporine was started on day 23 at 4.5 mg/kg twice
daily and continued until day 184 (n 5 66) or 1120
(n 5 42), followed by tapering if no GVHD was pres-
ent. Dose adjustments were made to keep cyclosporine
trough levels between 200 ng/mL and 400 ng/mL.
Moreover, cyclosporine dose was lowered when creat-
inine rise was caused by cyclosporine, at the discretion
of the physician. MMF was started 5 hours after graft
infusion at 15 mg/kg/day, with a maximum dose of 3
g/day until day128 (n5 66) or184 (n5 42), followed
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agnosed according to the Seattle criteria [29]. aGVHD
grade I was treated with topical corticosteroids.
aGVHD grade II or higher was treated with high-
dose systemic corticosteroids. Limited cGVHD was
not treated and extensive cGVHD was treated with cy-
closporine, systemic or topical corticosteroids, MMF,
or a combination of these drugs.
Infection prevention consisted of ciprofloxacin and
fluconazole, given orally, until granulocyte counts
exceeded 500 cell/mL. Co-trimoxazol 480 mg twice
daily was given for 15 months and valacyclovir 500
mg twice daily was given for 12 months, both orally.
Statistical Analysis
Continuous variables are displayed as the median,
with the range in parentheses. For dichotomous vari-
ables, the frequency of occurrence is given along with
the corresponding percentage. For comparison of
characteristics between groups, a chi-square test was
used to compare proportions, and 2-sided Student’s
t-test to compare continuous outcomes.
Those parameters reaching a univariable signifi-
cance level of P # .1 were assessed for significance
using multiple logistic regressions. Kaplan-Meier sur-
vival curves were made for overall survival (OS).
Curves were compared with a log-rank test. All P-
values were 2 sided, and a value of\.05 was considered
statistically significant. Analysis was performed using
SPSS version 12.0 (SPSS Inc., Chicago, IL).
Competing risk data were used to make a cumula-
tive incidence for CKD, wherein outcome is CKD,
competing risk is death without CKD, and time vari-
able is time to CKD, death, or last follow-up, which-
ever was first. This analysis was performed using
a R-library for multistate models and SPSS version
15.0 [30].
RESULTS
CKD stage 3 (GFR\60 mL/min/1.73 m2) devel-
oped in 14 patients (13%) and CKD stage 4 (GFR
\30 mL/min/1.73 m2) developed in 2 patients (2%)
after a median of 15 months (range: 1-48 months).
None of the patients required dialysis. Median fol-
low-up for surviving patients was 29 months (range:
15-61). Cumulative incidence of CKD was 7% at 12
months, 14% at 24 months, 16% at 36 months, and
22% at 48 months (Figure 1). OS was 66% at 48
months. There was no difference in survival between
patients with and without CKD.
Pretransplant risk factors for CKD stage 3 and 4
were female sex (P 5 .021), older age (P 5 .040),
and lower GFR 1 month prior to SCT (P \ .001)
(Table 1). Patients older than 60 years (n 5 30), pa-
tients between 50 and 59 years (n 5 48), and patients
between 40 and 49 years (n 5 20) developed CKD in17%, 21%, and 5%, respectively. None of the patients
younger than 40 years (n 5 10) developed CKD. Pa-
tients with GFR\90 mL/min/1.73 m2 (n 5 47) pro-
gressed to CKD in 23% of cases, patients with GFR
between 90 and 120 mL/min/1.73 m2 (n 5 43) pro-
gressed to CKD in 12% of cases. None of the patients
with GFR.120 mL/min/1.73 m2 developed CKD. In
multivariate analysis only lower GFR 1 month prior to
SCT was associated with CKD stage 3 and 4 (P5 .027,
odds ratio 0.96, 95% confidence interval 0.924-0.995).
Diagnosis, high-risk malignancy, type of transplant,
conditioning regimen and a history of hypertension,
autologous transplantation, or vascular disease did
not differ between patients with or without CKD stage
3 and 4.
None of the complications after SCT was associated
with CKD (Table 1). Moreover, immune suppression
regimen (cyclosporine until day 184 and MMF until
day128 or cyclosporine until day1120 and MMF until
day 184), cyclosporine trough levels, or long-term
cyclosporine use in the case of cGVHD did not differ
between the groups with or without CKD. Three pa-
tients developed nephrotic syndrome, but none of
them developed CKD. No patient developed throm-
botic thrombocytopenic purpura, sinusoidal occlusion
syndrome, or SCT nephropathy. Patients who devel-
oped CKD had significantly lower hemoglobin (Hb)
at 12 months than patients who did not (Hb 8.0
mmol/L, range: 5.0-10.4 versus Hb 8.6 mmol/L, range:
5.8-10.5, P5 .036).
DISCUSSION
In this large single-center cohort of recipients of
nonmyeloablative SCT, 15% of patients developed
CKD after a median follow-up of 29 months. This is
higher compared to the general population of the
same age, where CKD is present in\10% [31]. The
Figure 1. Cumulative incidence and survival of patients with and
without chronic kidney disease (CKD).
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All Patients (%) CKD Grade 3 or 4 no CKD P
Multivariate OR
(95% CI)
Sex .021
Male 70 (64.8) 6 (37.5) 64 (69.6)
Female 38 (35.2) 10 (62.5) 28 (30.4)
Age 55 (20-66) 55.5 (44-65) 55 (20-66) .04
History
Autologous 46 (42.6) 8 (50.0) 38 (41.3) ns
Hypertension (.140/90 mmHg) 43 (39.8) 10 (62.5) 33 (35.9) ns
Vascular disease 10 (9.3) 2 (12.5) 8 (8.7)
Diagnosis ns
Acute myelogenous leukemia 17 (15.7) 0 (0) 17 (18.5)
Acute lymphoblastic leukemia 4 (2.7) 1 (6.3) 3 (3.3)
Chronic myelogenous leukemia 4 (2.7) 1 (6.3) 3 (3.3)
Severe aplastic anemia 4 (3.7) 0 (0) 4 (4.3)
Multiple myeloma 48 (44.4) 9 (56.3) 39 (42.4)
Other 31 (28.7) 5 (31.3) 26 (28.3)
Malignancy risk ns
High risk 87 (80.6) 14 (87.5) 73 (79.3)
Low risk 21 (19.4) 2 (12.5) 19 (20.7)
Type of transplant ns
Matched related donor 70 (64.8) 8 (50.0) 62 (67.4)
Partially matched related donor 7 (6.5) 2 (12.5) 5 (5.4)
Matched unrelated donor 31 (28.7) 6 (37.5) 25 (27.2)
Mismatch 15 (13.9) 4 (25.0) 11 (12.0)
Conditioning ns
Fludarabine/TBI 35 (32.4) 2 (12.5) 33 (35.9)
Fludarabine/TBI/ATG 41 (38.0) 8 (50.0) 33 (35.9)
TBI 32 (29.6) 6 (37.5) 26 (28.3)
Renal function
Estimated GFR -1 month 94 (62-156) 81.5 (62-102) 99 (63-156) \.001 0.96 (0.924-0.995)
Estimated GFR baseline 87 (61-187) 76 (66-120) 88.5 (61-187) ns
Creatinine -1month 73 (48-129) 77 (58-112) 72.5 (48-129) ns
Creatinine baseline 77 (47-112) 77 (57-101) 77 (47-112) ns
Immune suppression ns
Cyclosporine until 1 84 days 66 (61.1) 9 (56.3) 57 (62.0)
Cyclosporine until 1 120 days 42 (38.9) 7 (43.8) 35 (38.0)
Complications
Acute renal failure 32 (29.6) 6 (37.5) 26 (28.3) ns
Nephrotic syndrome 3 (2.8) 0 (0) 3 (3.3) ns
Hypertension within 100 days 30 (27.8) 5 (31.3) 25 (27.2) ns
Chronic hypertension 30 (27.8) 5 (31.3) 25 (27.2) ns
CMV reactivation 11 (10.2) 2 (12.5) 9 (9.8) ns
ICU admission 5 (4.6) 1 (6.3) 4 (4.3) ns
Acute GVHD grade 0-I 63 (58.3) 8 (50.0) 55 (59.8) ns
Acute GVHD grade II 33 (30.6) 6 (37.5) 27 (29.3) ns
Acute GVHD III-IV 12 (11.1) 2 (12.5) 10 (10.9) ns
Chronic GVHD limited 10 (10.9) 0 (0) 10 (9.3) ns
Chronic GVHD extensive 49 (45.4) 7 (43.8) 42 (45.7) ns
Hb at 12 months 8.3 (5.0-10.5) 8.0 (5.0-10.4) 8.6 (5.8-10.5) .036
Cyclosporine trough
level .400 ng/mL
54 (50.9) 8 (50.0) 46 (51.1) ns
Outcome ns
Alive 86 (79.6) 14 (87.5) 72 (73.3)
Deceased 22 (20.4) 2 (12.5) 20 (21.7)
TBI indicates total-body irradiation; ATG, antithymocyte globulin; GFR-1month, glomerular filtration rate 1 month prior to SCT in mL/min/
1.73 m2. Median (range); Creatinine-1 months, creatinine 1 month prior to SCT in mmmol/L. Median (range); CMV, cytomegalovirus; ICU,
intensive care unit; GVHD, graft-versus-host disease; Hb, hemoglobin in mmol/L. Median (range).cumulative incidence of CKD was 22% at 48 months,
which is slightly higher than a cumulative incidence of
CKD of 20% at 5 years seen after myeloablative SCT
at the same institution [12]. The most likely rationale
for this is that patients who develop CKD despite non-myeloablative conditioning regimen are of older age
and/or have more comorbidities.
The strongest risk factor for the development of
CKD was lower estimated GFR 1 month prior to
SCT in multivariate analysis. This was similar to our
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SCT [12]. Also, in community-based population stud-
ies, mildly reduced GFR is a predictor for the develop-
ment of kidney disease [32]. Suboptimal kidney function
therefore seems to predispose for CKD. Critical evalu-
ation of kidney function before SCT and adequate treat-
ment of risk factors for CKD (eg, hypertension and
diabetes) seems a logical approach for these vulnerable
patients.
A second risk factor for CKD was older age in
univariate analysis. This was also found in studies
on CKD after myeloablative SCT [5,12]. Cross-
sectional community studies showed progressive de-
cline in renal function with aging [25,32]. Renal aging
is a natural phenomenon with a course that is depen-
dent on a combination of genetic and environmental
factors [33]. The nonmyeloablative conditioning
before transplantation, and the immune suppression
regimen or infection prophylaxis used posttransplan-
tation, are candidate factors that progress the renal
aging process.
A third risk factor for CKD was female sex in
univariate analysis. This was also found in our earlier
study on CKD after myeloablative SCT [12]. Also,
studies in the general population showed a higher inci-
dence of CKD for women than for men [31,32], a rea-
son to modify the cutoff value for CKD for women in 1
study [32]. Awareness of CKD in women is lower,
which might be caused by overlooking CKD in older
women, who often have a serum creatinine that is in
the normal range for younger individuals [34].
Acute renal failure after nonmyeloablative SCT
was not associated with increased risk for CKD, in
contrast to previous studies [11,26]. Our system of fre-
quent monitoring of serum creatinine and performing
dose reductions of nephrotoxic medication in the case
of an acute rise in creatinine might prevent irreversible
renal damage in those patients. Cyclosporine use did
not influence the occurrence of CKD. It is known
that chronic cyclosporine use contributes to CKD in
patients after heart and lung transplantation [35].
Acute cyclosporine injury is usually reversible [36],
but there is also evidence that chronic cyclosporine
nephrotoxicity has reversible components [37]. Using
cyclosporine only for restricted periods and monitor-
ing of trough levels seems to be a safe method to pre-
vent cyclosporine nephrotoxicity in patients after
SCT. Also, cGVHD was not a risk factor for CKD,
in contrast to other studies [4,11,26]. The postulated
independent role in development of CKD for cGVHD
with chronic inflammation and cyclosporine use there-
fore could not be confirmed by our study [17].
No patient developed SCT nephropathy, which is
in line with results of a previous study after nonmye-
loablative SCT [26]. The low dose of TBI in nonmye-
loablative SCT in comparison with myeloablative
SCT may account for this.The mechanisms by which CKD is caused after
nonmyeloablative SCT are still unknown, but a throm-
botic microangiopathic syndrome caused by radiation
is very unlikely. A combination of factors (eg, chemo-
therapy, TBI, nephrotoxic medication, and GVHD)
might cause CKD in susceptible patients because
they are of older age, have female sex, or, most
important, have decreased kidney function.
Patients with CKD had slightly lower hb levels
compared to patients without CKD. This is as ex-
pected, and underscores the importance of identifying
patients with GFR \60 mL/min/1.73m2 because of
increased morbidity under this cutoff value [10].
Finally, survival was not influenced by CKD in this
cohort. The reason for this might be that follow-up
was still too short for development of late complica-
tions of CKD.
In conclusion, CKD is a frequent complication af-
ter nonmyeloablative SCT. Women, patients above 50
years of age, and patients with slightly decreased kid-
ney function pretransplant have the greatest risk of
development of CKD. Multiple factors are thought
to influence the development of CKD, but the exact
mechanism needs further study.
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